Certain patients with non-small cell lung cancer who are treatment-naive may benefit from receiving a biopsy regarding treatment decision-making. Receiving genomic testing (looking for cancer cells ...
NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer and ...
An expert discusses the 2025 NCCN guideline updates for ROS1-positive non-small cell lung cancer, highlighting the inclusion of taletrectinib and repotrectinib as preferred first-line therapies due to ...
An expert explained what ROS1-positive non-small cell lung cancer is and why it is important to identify mutations like ROS1 through genetic sequencing. ROS1-positive non-small cell lung cancer, a ...
An expert discusses the personalized approach to treating ROS1-positive non-small cell lung cancer, emphasizing the preference for next-generation TKIs like taletrectinib and repotrectinib due to ...
NEW YORK--(BUSINESS WIRE)--AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today announced positive ...
Durable activity of NVL-655 and zidesamtinib in heavily pre-treated patient populations supports ongoing Phase 2 investigation in earlier lines of treatment "Our development strategy has been anchored ...
The FDA approved taletrectinib (Ibtrozi)-- a next-generation oral ROS1 tyrosine kinase inhibitor (TKI) -- for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell ...
Nuvalent (NASDAQ:NUVL) reported promising results from its mid-stage trial for zidesamtinib, a new drug that specifically targets ROS1, in patients with advanced ROS1-positive non-small cell lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback